Care Bare Rx Review: The NAD+ Price on the Site Is Not a Price

The one-sentence version

Care Bare Rx publishes more about who prescribes and who dispenses than almost anything else on this board — four pharmacies with street addresses and phone numbers, four clinicians with NPI numbers you can look up — and then advertises an NAD+ price that matches nothing in its own catalogue. The site says "NAD+ Treatments Starting at $199", directly beneath the words "Transparent pricing". Its catalogue holds exactly one NAD+ product, at $325 a month. It grades B, 9 points out of 14, computed from published terms alone and blind to who pays us — Care Bare Rx is a paid partner here.

What it is, and who it's for

Care Bare Rx is a telehealth brand positioned around LGBTQ+ care — "a wellness brand designed for those who want their health routine to feel as good as it looks" — running on CareGLP by CareValidate, with intake at intake.carebarerx.com and Stripe at checkout. The backend organisation is CareBareHealth.

The line this board ranks is three products: NAD+ injection (200 mg/mL, 10 mL), sermorelin acetate injection (2 mg/mL, 10 mL) and B-12 methylcobalamin (5 mg/mL). Beside them sit compounded semaglutide and tirzepatide with dose-tiered pricing, brand-name GLP-1s, a hair line and a sexual-health line. There is no glutathione, no other growth-hormone peptide, no methylene blue, no TRT or HRT and no supplements.

Note the dose tiering, because it is a real point in Care Bare's favour and its sibling brands do not do it: compounded semaglutide is $199 at 0.25 mg, $249 at 0.5 and 1 mg, $299 at 1.5 and 2 mg, and tirzepatide $299 / $349 / $399 across its three bands. A buyer can see what titrating up will cost before starting. Synergy Rx, on the same platform, strips that ladder out entirely.

The price problem, in three parts

1. The advertised NAD+ figure is purchasable at no tier. Every marketing page carries "NAD+ Treatments Starting at $199", and on the homepage that line sits in a block whose own bullet points include "Transparent pricing, discreet delivery, real results." The catalogue served from Care Bare's own intake system — unauthenticated, with prices switched on, so this is published information and not a leak — has one NAD+ product. It costs $325. There is no $199 tier, no $199 dose, no $199 promotional rung. The number is not a prepay rate that turns out to need twelve months, and not an intro month that steps up at the first refill. Those at least correspond to something somebody pays. This one corresponds to nothing.

2. The lander an affiliate link lands on advertises a third set of numbers. Care Bare runs a marketing lander at /home2, and it is where our own link resolves. It shows Ozempic at $749, hair at $99 and sexual health at $99. The /about and /faq pages show $705, $180 and $120 — and the checkout catalogue agrees with those. So a reader arriving from an ad lands on the page whose figures are wrong, and finds the corrected ones only if they navigate away from it. We checked whether a different landing page could be selected instead; there is not one.

3. The bundles are labelled in the wrong unit. On /gluca, "Semaglutide 3-Month Bundle From $748/mo" is a three-month total — $249 a month — and "Tirzepatide 3-Month Bundle From $1068/mo" is $356 a month. The "/mo" is on a figure that is not monthly.

What that costs, and why. Our rubric asks for one all-in figure, visible before you commit, that a buyer with no commitment actually pays. Care Bare has such a figure — $325, month-to-month, no prepay term — but it is not on any page a shopper reads, and the figure that is on those pages is off by 63%. Price transparency scores zero, and it is the same call Gala Health gets for advertising a yearly rate as though it were monthly. Compare Sprout Health, whose $199 headline is a genuine first-month rate with the $249 standing rate published beside it, and which keeps all four points. The difference is not honesty of intent — it is whether the number on the page is a number somebody is charged.

And two costs that are not in any headline. An $80 telehealth consult fee applies "if medication isn't prescribed" — stated in the catalogue's own fineprint rather than on the marketing pages. And the Terms make medical consult fees non-refundable and state that all sales are final.

What Care Bare publishes that most of this board does not

Four dispensing pharmacies, named, with street addresses and phone numbers, on its own FAQ:

• •Belmar Pharmacy — 6597 N 92nd St, Suite 105, Scottsdale, AZ 85260 · 800.525.9473
• •Strive Pharmacy — 21143 Hawthorne Blvd, Suite 305, Torrance, CA 90503 · 855.405.5993
• •Epiq Scripts — 625 Herndon Ave, Suite D, Clovis, CA 93612 · 833.654.3553
• •Casa Pharma Rx — 12855 Capricorn St, Stafford, TX 77477 · 877.937.6868

What it does not do is classify them. The only mention of the statute on that page is a general compliance list — "State boards of pharmacy, which regulate all 503A pharmacies" — which is an explanation of who regulates whom, not a statement that your prescription is filled under 503A. Our published methodology draws that line deliberately, so Care Bare takes the middle rung: one point of two, for naming without classifying.

Four clinicians, named, with NPI numbers. The clinical group is Lion MD: Dr. Ana Lisa Carr, MD (NPI 1689841744) and Dr. Kelly Tenbrink, MD (NPI 1346482684) leading, with Dr. HirenKimar Italia, MD (NPI 1487815387) and Dr. David Mansour, DO (NPI 1689164949) as supporting medical team. Four checkable identifiers is more than any other row in this batch publishes.

Belmar, and the thing to know in proportion. One of those four pharmacies, Belmar, received an FDA warning letter issued 31 March 2023, addressed to "Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy" — and FDA closed it out on 30 October 2023. We do not restate what it alleged; that is FDA's document to characterise, and the searchable index is linked below¹. Two things matter. The letter is closed out, and any page that leaves that off is publishing a false impression. And you only know about it because Care Bare names its pharmacies: the rows on this board that name nobody could be dispensing through anyone, and there would be nothing for you to check. Care Bare Rx itself holds no FDA warning letter — a live index search for "carebarerx", "care bare", "carebarehealth", "carevalidate" and "careglp" returned no company match, in a pass where a known-lettered company came back positive, so the clean result is real and not a broken query.

Support and oversight are inside the price. The homepage's own three-step explainer ends with "Ongoing Support & Delivery — We ship your meds directly to you with follow-up care and optional coaching." Follow-up care stated as part of the programme is what our support factor asks for; the coaching is hedged as optional and is not what the point is given for. And because the only consult charge published is the $80 that applies when nothing is prescribed, the clinician review sits inside the medication price for anyone who is prescribed.

The states question, and its answer

Care Bare's FAQ says: "We provide service to all 50 states and Puerto Rico."

Its own catalogue copy says something else. B-12 carries a no-ship list — Alabama, Arkansas, Alaska, Connecticut, Indiana, Kentucky, Louisiana, Michigan, Minnesota, Vermont and Wisconsin — and NAD+ in those same eleven states "will be supplied by secondary pharmacies. Cost may vary."

Both sentences are live. The reconciliation is that the GLP-1 line may well be fifty-state while the wellness line is not, and that the NAD+ price is not fixed everywhere even where the product is available. If you live in one of the eleven, get your own number in writing before paying.

Two smaller things in the same register: the homepage testimonials are recycled from CareGLP, the white-label platform behind the brand — one of them praises "what I expected from CareGLP" rather than Care Bare — and Mounjaro is flagged sold out in the catalogue while still being advertised on the marketing pages.

The evidence behind what it sells

This board grades providers, not molecules, and Care Bare markets within the category's normal register. But NAD+ at $325 a month is $3,900 a year, so the evidence belongs in the decision.

The 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness screened 113 studies including 33 human intervention trials. Oral precursors reliably raise blood NAD+³, but effects on functional, metabolic and vascular outcomes were "heterogeneous and often null or endpoint-specific," and clinical effectiveness for anti-aging or wellness "remains inconclusive"⁴. On the route Care Bare sells, the same review is blunter still: no eligible outcomes trial has evaluated injected NAD+ for these indications⁴. A 2025 meta-analysis in adults averaging over 60 found NAD+ precursors did not improve muscle index, grip strength, gait speed or chair-stand time⁵.

Sermorelin is a growth-hormone-releasing analogue, and the honest summary of GH augmentation in healthy older adults remains the 2007 Annals systematic review: small body-composition changes, no demonstrated functional benefit, more adverse events⁶. Compounded NAD+ and sermorelin are not FDA-approved, and FDA's own position is that compounded drugs are not FDA-approved and it does not verify their safety, effectiveness or quality before marketing². Read what the NAD+ evidence actually supports before deciding a year of this is worth it.

Where it's weak, and who should skip it

Skip it if you budget from the advertised number, because the advertised number is not the number — plan for $325 a month for NAD+, not $199. Skip it if you arrive on the /home2 lander and want to buy what it shows you, because its Ozempic, hair and sexual-health figures are not the ones the checkout charges. Skip it if you live in one of the eleven no-ship states and need a fixed NAD+ price, because Care Bare says explicitly that yours may vary. And skip it if a non-refundable consult fee and an all-sales-final policy are risks you will not take.

Buy it if the disclosure is what you are actually shopping for and you are prepared to confirm the price yourself. Four named pharmacies with addresses, four named clinicians with NPI numbers, a published dose ladder on the GLP-1 line, month-to-month with no prepay term and follow-up care inside the price is a genuinely strong package — attached to marketing copy that has not been reconciled with the catalogue behind it.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Care Bare takes the full four for its longevity line — NAD+, sermorelin and B-12 are what this board ranks — two for clinical oversight, because the consult is inside the medication price unless nothing is prescribed, two for support, on published follow-up care, and one of two for pharmacy, for naming four facilities without classifying any. It takes zero for price transparency, because the figure it advertises for the product this board grades is purchasable at no tier. Nine out of fourteen: a B.

The fix is a single line of copy. Change "Starting at $199" to "$325 a month" and Care Bare moves to thirteen and an A without touching the medicine, the pharmacies, the clinicians or the price itself. That is worth stating plainly, because it locates the problem exactly: this is not a company hiding what it charges — it is a company advertising a number nobody in its own system can sell you. The full graded field is at our provider rankings, and what this category costs generally is in longevity clinic cost.